Market Overview

The Daily Biotech Pulse: FDA Snub For Allergan, Myriad's Q4 Beat, Mallinckrodt's Stannsoporfin

The Daily Biotech Pulse: FDA Snub For Allergan, Myriad's Q4 Beat, Mallinckrodt's Stannsoporfin
Related IBB
The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug
The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US
An Economic Family That Trades Together… (TalkMarkets)
28 Stocks Moving In Monday's Pre-Market Session
FDA Snubs Mallinckrodt's Abuse-Deterrent Opioid Reformulation
Study links opioid prescriptions to marketing spend (Seeking Alpha)

Here's a roundup of top developments in the biotech space over the last 24 hours.

Scaling the Peaks

(Stocks hitting 52-week highs on Aug. 21)

  • Acer Therapeutics Inc (NASDAQ: ACER)
  • Avanos Medical Inc (NYSE: AVNS)(Raymond James upgraded the shares from Market Perform to Outperform)
  • Becton Dickinson and Co (NYSE: BDX)
  • BioLife Solutions Inc (NASDAQ: BLFS)
  • DexCom, Inc. (NASDAQ: DXCM)
  • Emergent Biosolutions Inc (NYSE: EBS)
  • Masimo Corporation (NASDAQ: MASI)
  • Medtronic PLC (NYSE: MDT)(reported above-consensus Q2 EPS)
  • Merck & Co., Inc. (NYSE: MRK)
  • Neogen Corporation (NASDAQ: NEOG)
  • Repligen Corporation (NASDAQ: RGEN)
  • Teva Pharmaceutical Industries Ltd (ADR) ADR (NYSE: TEVA)
  • Seattle Genetics, Inc. (NASDAQ: SGEN)

Down In The Dumps

(Stocks hitting 52-week lows on Aug. 21)

  • Pain Therapeutics, Inc. (NASDAQ: PTIE)
  • Trinity Biotech plc (ADR) (NASDAQ: TRIB)

See Also: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Stocks In Focus

Allergan Receives CRL For its Uterine Bleeding Medication

Allergan plc (NYSE: AGN) said the FDA issued a complete response letter, or CRL, for its ulipristal acetate for treating abnormal uterine bleeding in women with uterine fibroids.

The company noted that the FDA cited safety concerns regarding ESYMA post-marketing reports outside the U.S.

The stock slid 2.1 percent to $187.10 in after-hours trading.

Myriad Genetics Q4 EPS Beats Estimates; Guidance Trails

Myriad Genetics, Inc. (NASDAQ: MYGN) reported fiscal year fourth-quarter revenues of $200.9 million compared to $199.6 million last year. Adjusted earnings per share rose from 29 cents to 38 cents, ahead of the 33 cents per share consensus estimate. However, the fiscal-year 2019 guidance came in below expectations.

The stock rose 1.07 percent to $43.30 in after-hours trading.

On The Radar

Mallinckrodt PLC (NYSE: MNK) recived a CRL from the FDA on its Stannsoporfin for treating neonates at risk for developing severe hyperbilirubinemia, or severe jaundice. The FDA provided guidance regarding areas of further evaluation for resubmitting Stannsoporfin NDA. Until the company meets with FDA, it doesn't expect to make decision related to future efforts in the development of the product

Posted-In: Biotech Earnings News FDA Top Stories Trading Ideas Best of Benzinga


Related Articles (AGN + ACER)

View Comments and Join the Discussion!

Everything You Need To Know From The Cannabis Capital Conference

24 Stocks Moving In Wednesday's Pre-Market Session